UBS Group’s Dova Pharmaceuticals DOVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
– Sell
-58,035
Closed -$1.62M – 8742
2019
Q3
$1.62M Buy
58,035
+57,191
+6,776% +$927K ﹤0.01% 3513
2019
Q2
$12K Buy
844
+544
+181% +$5.17K ﹤0.01% 6987
2019
Q1
$3K Sell
300
-1,534
-84% -$12.5K ﹤0.01% 7397
2018
Q4
$14K Sell
1,834
-445
-20% -$7.16K ﹤0.01% 7070
2018
Q3
$48K Buy
2,279
+1,279
+128% +$30.5K ﹤0.01% 6195
2018
Q2
$30K Buy
+1,000
New +$27.2K ﹤0.01% 6398
2017
Q4
– Sell
-94
Closed -$2K – 8267
2017
Q3
$2K Sell
94
-2,406
-96% -$57K ﹤0.01% 7523
2017
Q2
$56K Buy
+2,500
New +$52.6K ﹤0.01% 5574

UBS Group's DOVA Position: Q4 2019 in Review

UBS Group sold out of Dova Pharmaceuticals (DOVA) in Q4 2019, closing a stake of 58,035 shares — an estimated $1.62M sold.

UBS Group first reported a position in DOVA in Q2 2017 and held it in 8 quarters. The position peaked at $1.62M in Q3 2019. 0 funds tracked by Wall St. Rank hold DOVA as of Q4 2019.

  • UBS Group reported no remaining Dova Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • UBS Group sold 58,035 Dova Pharmaceuticals shares in Q4 2019, an estimated $1.62M.
  • UBS Group first reported a position in Dova Pharmaceuticals in Q2 2017 and held it in 8 quarters.
  • UBS Group's Dova Pharmaceuticals position peaked at $1.62M in Q3 2019.
  • 0 funds tracked by Wall St. Rank held Dova Pharmaceuticals as of Q4 2019.

Based on UBS Group's 13F filing for Q4 2019, filed 14 Feb 2020.